Clinical Trial

Treatment of Advanced Solid Tumors

Study Description

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

The purpose of the dose escalation part of this study is to determine the feasibility of using the combination of copanlisib and nivolumab in subjects with advanced solid tumors, and to determine the maximum tolerated dose of copanlisib in combination with nivolumab. The maximum tolerated dose will then be used in Phase 2 (dose expansion) of the study.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Copanlisib

Copanlisib: lyophilisate for reconstitution and further dilution for infusion

Drug - Nivolumab

Nivolumab: concentrate for solution for infusion

Additional Information

Official Study Title

An Open-label, Multi-center, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors.

Clinical Trial ID

NCT03735628

ParticipAid ID

dwpEwe